Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Earlier use of ciltacabtagene autoleucel (cilta-cel) is associated with better immune fitness and stronger immune effects as shown by correlative analysis of peripheral blood and the bone marrow tumor microenvironment (TME) from the CARTITUDE-4 study

View Full Paper
Ask AI
Bookmark
Share

Authors

NDNiels W.C.J. van de DonkSHShuo HanMSMahipal Suraneni

Discussion

Loading...

Member takes

Overview

Correlative analysis reveals cilta-cel improves progression-free survival in multiple myeloma, suggesting enhanced immune responses and biomarker profiles.

Key Points

  • This research aims to investigate the correlation between immune responses and survival outcomes in multiple myeloma patients treated with cilta-cel.
  • Used biomarker analyses on peripheral blood and bone marrow samples from CART-1 and CART-4 studies.
  • Performed immunophenotyping through flow cytometry on baseline samples.
  • Analyzed gene expression from bone marrow aspirates to derive set enrichment scores related to the tumor microenvironment.
  • Evaluated progression-free survival in relation to treatment history and immune fitness.
  • Cilta-cel showed significant overall survival benefits with increased minimal residual disease negativity.
  • Higher baseline CD4+ naïve T cells correlated with longer progression-free survival.
  • Depletion of B cells and increased cytokine signaling observed post cilta-cel infusion.
  • Higher levels of tumor-associated macrophages associated with better survival outcomes.

Cite This Study

Donk et al. (2025) studied this question.

synapsesocial.com/papers/693624d44fa91c937236d04chttps://doi.org/10.1182/blood-2025-92
View Full Paper
Ask AI
Bookmark
Share